XtalPi AI-Designed PEP08 PRMT5 Inhibitor Approved for Phase I
September 10, 2025 | 16:09
Algorithm-to-clinic success slashes discovery time 30%—Taiwan FDA green-lights first-in-human trials targeting rare solid tumors.
Mobile Version